1. Educational Experience
2010.09-2015.06, Ph.D, Department of Pharmaceutical Analysis, China Pharmaceutical University.
2. Working Experience
Since 2015.07, Department of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University.
2017.03-2020.03, Postdoctor, School of Chemistry and Chemical Engineering, Nanjing University.
1. Biological drugs analysis.
2. Biopharmaceutical analysis.
3. Drug quality standards and control.
4. New drug development and evaluation.
1. Research Projects
(1) National Natural Science Foundation of China (No.81603072)
(2) Open Project Program of MOE Key Laboratory of Drug Quality Control and Pharmacovigilance (No. DQCP20/21PQ02)
(3) Key projects of basic scientific research in central universities (No. 2632019ZD19)
(4) Open Project Program of MOE Key Laboratory of Drug Quality Control and Pharmacovigilance (No. DQCP2017QN03)
(5) Open Project of Jiangsu Province Key Laboratory of Characteristic Resources Development and Pharmaceutical Research (No. LPRK202102)
(6) Postdoctoral Research Fund of Jiangsu Province (No. 1701090C)
2. Representative Research Achievements
(1) Biological drugs and Biopharmaceutical analysis.
(2) Drug quality standards and control.
(3) New drug development and evaluation.
1. Hu P, Huang R, Xu Y, Li TF, Yin J, Yang Y, Liang Y, Mao X, Ding L and Shu C*, Novel and sensitive ratiometric fluorescent quantum dot-based biosensor for alkaline phosphatase detection in biological samples via the inner-filter effect, Rsc Advances, 2023; 13:2311-2317. (IF = 4.036)
2.Shu C, Li T, Li D, Li Z, Xia X*，A sensitive and validated LC-MS/MS method for high-throughput determination of pomalidomide in human plasma and pharmacokinetic studies, Chinese Chemical Letters, 2022; 33:916-919. (IF = 8.455)
3.Shu C, Li T, Li D, Li Z, Xia X*，Barcode signal amplifying strategy for sensitive and accurate protein detection on LC-MS/MS, Analyst, 2021; 146:1364-5528；(IF = 5.221)
4.Xu Q1, Shu C 1, Li Y, Zhuang R, Jiang L and Xu X*, Controllable mixed-charged co-assembly of dendritic lipopeptides into invisible capsid-like nanoparticles as potential drug carriers, Chem Commun, 2021; 57: 4859-4862; (IF = 6.160)
5.Man J, Jiao F, Wang Y, Gu Y, Ding L*, Shu C*, Determination of benzonatate and its metabolite in human plasma by HPLC–MS/MS: A preliminary pharmacokinetic study in healthy Chinese volunteers after oral administration of benzonatate soft capsule, Journal of Pharmaceutical and Biomedical Analysis, 2019; 173 :134–143. (IF = 3.125)
6.Li T, Huang B, Li D, Ding L, Shu C*. Development and validation of a specific and sensitive LC–MS/MS method for determination of eslicarbazepine in human plasma and its clinical pharmacokinetic study. Journal of Chromatography B , 2019; 1112:61-66. (IF = 3.148)
7.Shu C, Li T, Li D, Zhu Y, Tang Y, Kong Y, et al. Anticancer activity and pharmacokinetics of TanshinoneⅡA derivative supramolecular hydrogels. Journal of Drug Delivery Science and Technology 2018; 48:509-15. (IF = 2.875)
8.Shu C, Sabi-Mouka EMB, Wang X, Ding L. Self-assembly hydrogels as multifunctional drug delivery of paclitaxel for synergistic tumour-targeting and biocompatibility in vitro and in vivo. The Journal of pharmacy and pharmacology 2017; 69:967-77. (IF = 2.462)
9.Shu C, Sabi-mouka EMB, Yang W, Li Z, Ding L. Effects of paclitaxel (PTX) prodrug-based self-assembly peptide hydrogels combined with suberoylanilide hydroxamic acid (SAHA) for PTX-resistant cancer and synergistic antitumor therapy. RSC Advances 2016; 6:100765-71. (IF=3.033)
10.Shu C, Li R, Yin Y, Yin D, Gu Y, Ding L, et al. Synergistic dual-targeting hydrogel improves targeting and anticancer effect of Taxol in vitro and in vivo. Chemical Communications 2014; 50:15423-6. (IF = 6.391)
